DOCSLIB.ORG

Free Trial Antibody

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Free Trial Antibody 3,000 FREE TRIAL Antibodies (Page21-133) Peptide Synthesis Best Price Custom Peptides High Quality Peptide Libraries Antibody Services Quick Turnaround cGMP Peptides mg to kg Amounts Modifications CATALOG ANTIBODY Protein Purification RISK FREE CUSTOM POLYCLONAL ANTIBODY E. coli Codon optimization Yeast Expression system evaluation 45-Day Detection Custom Monoclonal Antibody Insect cells Systematic testing of expression Mammalian cells From lab scale to 5g/L *Policy: Shipping fee will be waived if customers provide FEDEX number or is visited by our staff. Email: [email protected] web: www.NeoBioLab.com Alternatively, NEO can send samples with other orders. Each lab enjoys 2 free trial antibodies, Global Headquarters: 245 1st Street, Cambridge Science Center 18 F, MA USA 02142 Tel: 888.754.5670 each additional sample will be charged, but can be refunded after receiving test data. Euro Headquarters: 34 South Molton St., #307, Mayfair, London, W1K5RG UK Tel: +44 020.8123.1558 Research Center: 395 W Cummings Park, Woburn, MA 01801 Tel: +1(617) 500-7103 NeoBiolab.com Accelerate Your Biomolecule and Bioassay Research Gene Synthesis Protein Services Bioassays Open Source Peptide Synthesis Antibody Services More than 3,000 free trial antibodies (2014-2015) Serving Science Sharing Science Peptide Services Antibody Services Next-Day-Peptides 45-Day mAb Custom Peptide Synthesis Polyclonal Antibodies Peptide Library Monoclonal Antibodies GMP Peptide PO4-specific Antibodies Peptide Modification Antibody 2.0: MassAb GlycoPeptide Peptide Nucleic Acid (PNA) Protein Services Gene Services Promoter 2.0: 100X CMV Guarantee the Best Price Codon Optimization Gene Synthesis Bacterial Expression Sub-Cloning Yeast Expression Mutagenesis Baculovirus Expression Gene Ready Clones Mammalian Cell Expression Codon Optimization Protein Structure Proteomics Co-R&D Product Data Strategy 3,000 FREE TRIAL Antibodies* Open Shipping fee will be waived if customers provide FEDEX number or is visited by our staff. Alternatively, NEO can send samples with other orders. Each lab enjoys 2 free trial antibodies, Source each additional sample will be charged, but can be refunded after receiving test data. Antibodies IPs Antibodies can be used for the following areas Angiogenesis Transcription Factor Apoptosis Ubiquitin-Protein Proteins Autophagy Hedgehog Signaling Pathway Centrosomal Protein Hippo Signaling Pathway DNA Damage/Repair Jak-Stat Signaling Pathway Epigenetics & Nuclear Function NF-kB Signaling Pathway Ion Channel Regulation P38 MAPK Signaling Pathway Mitochondrial Biogenesis TGFB-Smad Signaling Pathway Neurodegenerative Diseases Toll-Like Receptor Signaling Pathway RNA Binding Protein Wnt/Notch Signaling Pathway Products Proteins Cytokines and GPCR Antibodies (Free trial) ELISA Kits (>10,000) Proteins from Mammalian System Protein-free Medium Transfection Reagents Monoclonal Antibody Library NEO is expressing and purifying cytokine and re-engineered GPCR proteins from mammalian cells. The proteins have PTM, which reflects the real human proteins rather than the backbone from bacteria. The proteins will be used to develop monoclonal antibody libraries. We provide next day delivery Broad Choices for Synthesis Service Features: Modified residues High Success Rate: >98% Fluorescent labels Fast Turnaround Time: 2-3 weeks Biotinylated peptides Length up to 200 amino acids Acetylation Isotopic labeling Quantity: from mg to kg scales Amidation Purities: up to 99% Fatty acid capping Various peptide modifications Cyclic peptides Peptide conjugations: BSA, KLH, etc Succinylation Competitive Prices: 30% below market prices Branched peptides NeoPeptide™ Technology: Liquid phase peptide synthesis (LPPS): for shorter peptides. Large-scale solid phase peptide synthesis (SPPS): for longer, more complex sequences. Microwave technologies: Custom Peptides increase chemical coupling efficiency, enhance success rate and improve peptide yields. Proprietary ligation technology: allows the joining of peptides of up to 200 amino acids. MS & HPLC Order Synthesis Purication MS & HPLC Product (with data) QC & QA References Clin Vaccine Immunol. Jun 2013; 20(6): 789–794. Comparative Efficacy of Two Leading Candidate Ricin Toxin A Subunit Vaccines in Mice Proc Natl Acad Sci U S A. Jan 28, 2014; 111(4): 1288–1292. Efficient and directed peptide bond formation in the gas phase via ion/ion reactions Mol Cell. 2014 Sep 4;55(5):733-44. Lysine acetylation controls local protein conformation by influencing proline isomerization. Email: [email protected] Tel: +1(888) 754-5670 or +1(617) 500-7103 (Int’l) +44 (020) 8123.1558 +91 987.367.1153 web: www.NeoBiolab.com MassPep ™ Technologies The most efficient high-throughput peptide library MassPep™ are NEO's synthetic peptide libraries - sets of chemically synthesized peptides, made on a small scale using our unique parallel array synthesis techniques. Made on a standardized scale to yield at least 1 micromole of each peptide. MassPep comprising hundreds, or even thousands of peptides, are readily synthesized in 2-3 weeks. They are most commonly used for primary screens, but are also available at >95% purity. Peptide Library Overlapping Truncation T-cell Truncated Alanine Scan Combinatorial Combinatorial Positional Scan Scrambled 2-Positional Scan 3-Positional Scan Email: [email protected] web: www.NeoBiolab.com Peptide Modifications Amidation (C-terminus) or Acetylation (N-Terminal), HYNIC (N-Terminal), Acetylation (N-terminus) DTPA (N-Terminal), Formylation (N-Terminal), Fatty FRET(fluorescence resonance energy transfer) MassPep acid (N-Terminal), Myristic acid (N-Terminal), Palmytolyl (N-Terminal), Benzyloxycarbonylation (CBZ), Amidation (C-Terminal), Succinylation (Suc, N-Terminal), etc. Special Amino Acids D-Arg, D-Cys, D-Asp, D-Asn, D-Glu, D-Gln, D-Ser, D-His, D-Thr, D-Trp, D-Leu,D-Ile, D-Met, D-Pro, D- Val ,D-Phe, pGlu, Hyp, D-Lys,D-Tyr, D-Orn, Orn, Abu, Aib, (D)1-Nal, (D)2-Pal, (D)4-Cl-Phe, Nva, Nle, Hse, Hcy, Pen, Mpa,N-Methyl amino acid (Ala, Phe, Leu, Ile, Val, Gly, Met),Other amino acid, Dinitrobenzoylation (Lys), Lys (Me2), Phosphorylation (Tyr, Ser, Thr, single site), Tyr(SO3H2), Ser (octanoic acid), etc. Fluorescence/Dye labeling Biotin (N-Terminal, Y/N Ahx), Biotin (Lys in sequence), Biotin (without Lys in sequence), FITC/5-FAM (N-Terminal, Y/N Ahx), Dansyl (N- Terminal, Y/N Ahx), MCA (N-Terminal), p- Nitroanilide (pNA, C-Terminal), AMC (C-Terminal) Multiple Disulfide Bonds NeoPeptide™ is able to build up to three disulfide bridges between cysteine at specified positions on one peptide. Multiple Phosphorylations NeoPeptide™ can synthesize serine-, threonine-, and tyrosine-phosphopeptides. For peptides containing one or more of these hydroxy-amino acids, selective phosphorylation can be achieved by orthogonal protection or by Fmoc-protected phosphorylated amino acids. Keyhole Limpet Hemocyanin To generate significant immune responses, (KLH), Bovine Serum Albumin peptides are conjugated to bigger carrier proteins, (BSA), and Ovalbumin such as ovalbumin, BSA or KLH. NeoPeptide™ couples the cysteine residue of the peptide to the carrier protein. PEGylation PEGylation is the covalent conjugation of macromolecules with polyethylene glycol (PEG), polymers that are nonionic, nontoxic, biocompatible and highly hydrophilic polymers. PEGylation enhances the therapeutic application of Modifications macromolecules. Isotope Labeling NeoPeptide™ can label peptides with stable nonradioactive isotopes, such as 2H, 15N, 13C, or both 15N and 13C. Multiple Antigenic Peptide Multiple antigenic peptides, consisting of highly (MAP) System localized peptide density and high molecular weight, is one potent way to produce high-titer antipeptide antibodies and synthetic peptide vaccines. This system utilizes lysine to form a backbone to which multiple peptide chains can be attached. NeoPeptideTM can form Asymmetric 4 branches and Asymmetric 8 branches. Quenched Fluorescent Peptide Abz/ Tyr (3-NO2), EDANS/DABCYL Use of Phosphopeptide Antibodies in a Phosphorylated MassPep ELISA Procedure with Biotinylated MassPep Screening Assay for Kinase Inhibitors Goat Anti- ATP Kinase rabbit IgG Labelled Detection Detection Antibody Antibody Anti-glutathione PHOSPHORYLATION S-transferase Rabbit Fusion Proteins Antipeptide/Protein Antibody for Shcr & Grb2 Antibody without inhibitor Immobilised Inhibitor with inhibitor Biotinylated Immobilized Peptide Immobilized Biotinylated Peptide Biotinylated Peptide pTyr Streptavidin Streptavidin Streptavidin Email: [email protected] Tel: +1(888) 754-5670 or +1(617) 500-7103 (Int’l) +44 (020) 8123.1558 +91 987.367.1153 web: www.NeoBiolab.com Peptide Nucleic Acids (PNA) PNAs are synthetic analogs of DNA in which the ribose phosphate backbone has been replaced by a polyamide chain. PNAs can be used in the same applications as conventional DNA/RNA oligomers.Because of their unique backbone, they have a number of advantages: PNAs bind to complementary DNA/RNA sequences with higher affinity and greater specificity than conventional oligonucleotides. PNAs are more stable than DNA or RNA and resistant to nucleases and proteases. PNAs can be hybridized at lower salt concentrations than DNA or RNA, which leads to higher stringency. PNAs make ideal reagents for antisense use, probes for molecular diagnostics and microarrays. Applications Services PNA and Glycopeptide Alteration of gene expression: inhibitor/promoter PNAs from 3-100 monomers Antigene and antisense therapeutic agent Scales from 50 nmole to 1mM Anticancer, antiviral, antibacterial,
Load more

Recommended publications
  • Covalent Flexible Peptide Docking in Rosetta
    bioRxiv preprint doi: https://doi.org/10.1101/2021.05.06.441297; this version posted May 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Covalent Flexible Peptide Docking in Rosetta Barr Tivon1,#, Ronen Gabizon1,#, Bente A. Somsen2, Peter J. Cossar2, Christian Ottmann2 , Nir London1,* 1 Department of Chemical and Structural Biology, The Weizmann Institute of Science, Rehovot, 7610001, Israel 2 Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, P.O. Box 513, 5600MB Eindhoven, The Netherlands # equal contribution * Corresponding author: [email protected] Keywords: Covalent peptides; peptide docking; CovPepDock; FlexPepDock; 14-3-3; Electrophilic peptides; bioRxiv preprint doi: https://doi.org/10.1101/2021.05.06.441297; this version posted May 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Electrophilic peptides that form an irreversible covalent bond with their target have great potential for binding targets that have been previously considered undruggable. However, the discovery of such peptides remains a challenge. Here, we present CovPepDock, a computational pipeline for peptide docking that incorporates covalent binding between the peptide and a receptor cysteine. We applied CovPepDock retrospectively to a dataset of 115 disulfide-bound peptides and a dataset of 54 electrophilic peptides, for which it produced a top-five scoring, near-native model, in 89% and 100% of the cases, respectively.
    [Show full text]
  • A Global Review on Short Peptides: Frontiers and Perspectives †
    molecules Review A Global Review on Short Peptides: Frontiers and Perspectives † Vasso Apostolopoulos 1 , Joanna Bojarska 2,* , Tsun-Thai Chai 3 , Sherif Elnagdy 4 , Krzysztof Kaczmarek 5 , John Matsoukas 1,6,7, Roger New 8,9, Keykavous Parang 10 , Octavio Paredes Lopez 11 , Hamideh Parhiz 12, Conrad O. Perera 13, Monica Pickholz 14,15, Milan Remko 16, Michele Saviano 17, Mariusz Skwarczynski 18, Yefeng Tang 19, Wojciech M. Wolf 2,*, Taku Yoshiya 20 , Janusz Zabrocki 5, Piotr Zielenkiewicz 21,22 , Maha AlKhazindar 4 , Vanessa Barriga 1, Konstantinos Kelaidonis 6, Elham Mousavinezhad Sarasia 9 and Istvan Toth 18,23,24 1 Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia; [email protected] (V.A.); [email protected] (J.M.); [email protected] (V.B.) 2 Institute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego˙ 116, 90-924 Lodz, Poland 3 Department of Chemical Science, Faculty of Science, Universiti Tunku Abdul Rahman, Kampar 31900, Malaysia; [email protected] 4 Botany and Microbiology Department, Faculty of Science, Cairo University, Gamaa St., Giza 12613, Egypt; [email protected] (S.E.); [email protected] (M.A.) 5 Institute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego˙ 116, 90-924 Lodz, Poland; [email protected] (K.K.); [email protected] (J.Z.) 6 NewDrug, Patras Science Park, 26500 Patras, Greece; [email protected] 7 Department of Physiology and Pharmacology,
    [Show full text]
  • Computational Modeling of Lysine Post-Translational Modification: an Overview Md
    c and S eti ys h te nt m y s S B Hasan MM et al., Curr Synthetic Sys Biol 2018, 6:1 t i n o e l Current Synthetic and o r r g DOI: 10.4172/2332-0737.1000137 u y C ISSN: 2332-0737 Systems Biology CommentaryResearch Article OpenOpen Access Access Computational Modeling of Lysine Post-Translational Modification: An Overview Md. Mehedi Hasan 1*, Mst. Shamima Khatun2, and Hiroyuki Kurata1,3 1Department of Bioscience and Bioinformatics, Kyushu Institute of Technology, 680-4 Kawazu, Iizuka, Fukuoka 820-8502, Japan 2Department of Statistics, Laboratory of Bioinformatics, Rajshahi University-6205, Bangladesh 3Biomedical Informatics R&D Center, Kyushu Institute of Technology, 680-4 Kawazu, Iizuka, Fukuoka 820-8502, Japan Commentary hot spot for PTMs, and a number of protein lysine modifications could occur in both histone and non-histone proteins [11,12]. For instance, Living organisms have a magnificent ordered and complex lysine methylation in non-histone proteins can regulate the protein structure. In regulating the cellular functions, post-translational activity and protein structure stability [13]. In 2004, the Nobel Prize in modifications (PTMs) are critical molecular measures. They alter Chemistry was awarded jointly to Aaron Ciechanover, Avram Hershko protein conformation, modulating their activity, stability and and Irwin Rose for the discovery of lysine ubiquitin-mediated protein localization. Up to date, more than 300 types of PTMs are experimentally degradation [14]. discovered in vivo and in vitro pathways [1,2]. Major and common PTMs are methylation, ubiquitination, succinylation, phosphorylation, Moreover, in biological process, lysine can be modified by the glycosylation, acetylation, and sumoylation.
    [Show full text]
  • Loss of Conserved Ubiquitylation Sites in Conserved Proteins During Human Evolution
    INTERNATIONAL JOURNAL OF MOleCular meDICine 42: 2203-2212, 2018 Loss of conserved ubiquitylation sites in conserved proteins during human evolution DONGBIN PARK, CHUL JUN GOH, HYEIN KIM, JI SEOK LEE and YOONSOO HAHN Department of Life Science, Chung‑Ang University, Seoul 06974, Republic of Korea Received January 30, 2018; Accepted July 6, 2018 DOI: 10.3892/ijmm.2018.3772 Abstract. Ubiquitylation of lysine residues in proteins serves Introduction a pivotal role in the efficient removal of misfolded or unused proteins and in the control of various regulatory pathways Ubiquitylation, in which the highly conserved 76‑residue poly- by monitoring protein activity that may lead to protein peptide ubiquitin is covalently attached to a lysine residue of degradation. The loss of ubiquitylated lysines may affect substrate proteins, mediates the targeted destruction of ubiq- the ubiquitin‑mediated regulatory network and result in the uitylated proteins by the ubiquitin‑proteasome system (1‑4). emergence of novel phenotypes. The present study analyzed The ubiquitin‑mediated protein degradation pathway serves a mouse ubiquitylation data and orthologous proteins from crucial role in the efficient and specific removal of misfolded 62 mammals to identify 193 conserved ubiquitylation sites from proteins and certain key regulatory proteins (5,6). Ubiquitin 169 proteins that were lost in the Euarchonta lineage leading and other ubiquitin‑like proteins, including autophagy‑related to humans. A total of 8 proteins, including betaine homo- protein 8, Ubiquitin‑like
    [Show full text]
  • 1 Design and Production of Specifically and with High Affinity
    1 Design and Production of Specifically and with High Affinity Reacting Peptides (SHARP®-s) by Jan C Biro HOMULUS FOUNDATION, 612 S. Flower Str., #1220, 90017 CA, USA [email protected] www.janbiro.com 2 Abstract Background A partially random target selection method was developed to design and produce affinity reagents (target) to any protein query. It is based on the recent concept of Proteomic Code (for review see Biro, 2007 [1]) which suggests that significant number of amino acids in specifically interacting proteins are coded by partially complementary codons. It means that the 1st and 3rd residues of codons coding many co-locating amino acids are complementary but the 2nd may but not necessarily complementary: like 5’-AXG-3’/3’-CXT-5’ codon pair, where X is any nucleotide. Results A mixture of 45 residue long, reverse, partially complementary oligonucleotide sequences (target pool) were synthesized to selected epitopes of query mRNA sequences. The 2nd codon residues were randomized. The target oligonucleotide pool was inserted into vectors, expressed and the protein products were screened for affinity to the query in Bacterial Two-Hybrid System. The best clones were used for larger-scale protein syntheses and characterization. It was possible to design and produce specific and with high affinity reacting (Kd: ~100 nM) oligopeptide reagents to GAL4 query oligopeptides. Conclusions Second codon residue randomization is a promising method to design and produce affinity peptides to any protein sequences. The method has the potential to be a rapid, inexpensive, high throughput, non-immunoglobulin based alternative to recent in vivo antibody generating procedures.
    [Show full text]
  • Metabolomics-Assisted Proteomics Identifies Succinylation and SIRT5 As Important Regulators of Cardiac Function
    Metabolomics-assisted proteomics identifies succinylation and SIRT5 as important regulators of cardiac function Sushabhan Sadhukhana, Xiaojing Liub,c,d, Dongryeol Ryue, Ornella D. Nelsona, John A. Stupinskif, Zhi Lia, Wei Cheng, Sheng Zhangg, Robert S. Weissf, Jason W. Locasaleb,c,d, Johan Auwerxe,1, and Hening Lina,h,1 aDepartment of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853; bDuke Cancer Institute, Duke University School of Medicine, Durham, NC 27710; cDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC 27710; dDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710; eLaboratory of Integrative and Systems Physiology, School of Life Sciences, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland; fDepartment of Biomedical Sciences, Cornell University, Ithaca, NY 14853; gProteomics & Mass Spectrometry Facility, Institute of Biotechnology, Cornell University, Ithaca, NY 14853; and hHoward Hughes Medical Institute, Cornell University, Ithaca, NY 14853 Edited by Kevan M. Shokat, University of California, San Francisco, CA, and approved March 9, 2016 (received for review October 7, 2015) Cellular metabolites, such as acyl-CoA, can modify proteins, leading SIRT4 and SIRT5 have very weak deacetylase activities (14). SIRT5 to protein posttranslational modifications (PTMs). One such PTM is possesses unique enzymatic activity on hydrolyzing negatively lysine succinylation, which is regulated by sirtuin 5 (SIRT5). Although charged
    [Show full text]
  • SUMO and Transcriptional Regulation: the Lessons of Large-Scale Proteomic, Modifomic and Genomic Studies
    molecules Review SUMO and Transcriptional Regulation: The Lessons of Large-Scale Proteomic, Modifomic and Genomic Studies Mathias Boulanger 1,2 , Mehuli Chakraborty 1,2, Denis Tempé 1,2, Marc Piechaczyk 1,2,* and Guillaume Bossis 1,2,* 1 Institut de Génétique Moléculaire de Montpellier (IGMM), University of Montpellier, CNRS, Montpellier, France; [email protected] (M.B.); [email protected] (M.C.); [email protected] (D.T.) 2 Equipe Labellisée Ligue Contre le Cancer, Paris, France * Correspondence: [email protected] (M.P.); [email protected] (G.B.) Abstract: One major role of the eukaryotic peptidic post-translational modifier SUMO in the cell is transcriptional control. This occurs via modification of virtually all classes of transcriptional actors, which include transcription factors, transcriptional coregulators, diverse chromatin components, as well as Pol I-, Pol II- and Pol III transcriptional machineries and their regulators. For many years, the role of SUMOylation has essentially been studied on individual proteins, or small groups of proteins, principally dealing with Pol II-mediated transcription. This provided only a fragmentary view of how SUMOylation controls transcription. The recent advent of large-scale proteomic, modifomic and genomic studies has however considerably refined our perception of the part played by SUMO in gene expression control. We review here these developments and the new concepts they are at the origin of, together with the limitations of our knowledge. How they illuminate the SUMO-dependent Citation: Boulanger, M.; transcriptional mechanisms that have been characterized thus far and how they impact our view of Chakraborty, M.; Tempé, D.; SUMO-dependent chromatin organization are also considered.
    [Show full text]
  • Deep Time-Resolved Proteomic and Phosphoproteomic Profiling Of
    Deep time-resolved proteomic and phosphoproteomic profiling of cigarette smoke-induced chronic obstructive pulmonary disease David Skerrett-Byrne BSc Biochem & Mol Bio (Hons)(UCD) MSc Biotech (UU) 25th March 2019 Supervisors: Professor Phil Hansbro, Dr. Matt Dun, Laureate Professor Rodney Scott, Professor Peter Wark, Professor Darryl Knight, Laureate Professor Paul Foster Discipline of Immunology and Microbiology and Priority Research Centre for Healthy Lungs School of Biomedical Science and Pharmacy Faculty of Health and Medicine University of Newcastle and Hunter Medical Research Institute Newcastle, NSW, Australia Submitted in fulfilment of the requirements for the award of a Doctor of Philosophy Declaration Statement of Originality I hereby certify that the work embodied in the thesis is my own work, conducted under normal supervision. The thesis contains no material which has been accepted, or is being examined, for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made. I give consent to the final version of my thesis being made available worldwide when deposited in the University’s Digital Repository, subject to the provisions of the Copyright Act 1968 and any approved embargo. ________________________ David Skerrett-Byrne 25/03/2019 Acknowledgment of Authorship I hereby certify that the work embodied in this thesis contains scholarly work of which I am a joint author. I have included as part of the thesis a written declaration endorsed in writing by my supervisor, attesting to my contribution to the joint scholarly work.
    [Show full text]
  • Ubiquitin Modifications
    npg Cell Research (2016) 26:399-422. REVIEW www.nature.com/cr Ubiquitin modifications Kirby N Swatek1, David Komander1 1Medical Research Council Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK Protein ubiquitination is a dynamic multifaceted post-translational modification involved in nearly all aspects of eukaryotic biology. Once attached to a substrate, the 76-amino acid protein ubiquitin is subjected to further modi- fications, creating a multitude of distinct signals with distinct cellular outcomes, referred to as the ‘ubiquitin code’. Ubiquitin can be ubiquitinated on seven lysine (Lys) residues or on the N-terminus, leading to polyubiquitin chains that can encompass complex topologies. Alternatively or in addition, ubiquitin Lys residues can be modified by ubiq- uitin-like molecules (such as SUMO or NEDD8). Finally, ubiquitin can also be acetylated on Lys, or phosphorylated on Ser, Thr or Tyr residues, and each modification has the potential to dramatically alter the signaling outcome. While the number of distinctly modified ubiquitin species in cells is mind-boggling, much progress has been made to characterize the roles of distinct ubiquitin modifications, and many enzymes and receptors have been identified that create, recognize or remove these ubiquitin modifications. We here provide an overview of the various ubiquitin modifications present in cells, and highlight recent progress on ubiquitin chain biology. We then discuss the recent findings in the field of ubiquitin acetylation and phosphorylation, with a focus on Ser65-phosphorylation and its role in mitophagy and Parkin activation. Keywords: ubiquitin; proteasomal degradation; phosphorylation; post-translational modification; Parkin Cell Research (2016) 26:399-422.
    [Show full text]
  • SUCLA2 Mutations Cause Global Protein Succinylation Contributing To
    ARTICLE https://doi.org/10.1038/s41467-020-19743-4 OPEN SUCLA2 mutations cause global protein succinylation contributing to the pathomechanism of a hereditary mitochondrial disease ✉ Philipp Gut 1,2,17 , Sanna Matilainen3,17, Jesse G. Meyer4,14,17, Pieti Pällijeff3, Joy Richard2, Christopher J. Carroll5, Liliya Euro 3, Christopher B. Jackson 3, Pirjo Isohanni3,6, Berge A. Minassian7,8, Reem A. Alkhater9, Elsebet Østergaard10, Gabriele Civiletto2, Alice Parisi2, Jonathan Thevenet2, Matthew J. Rardin4,15, Wenjuan He1, Yuya Nishida1, John C. Newman 1, Xiaojing Liu11,16, Stefan Christen2, ✉ ✉ Sofia Moco 2, Jason W. Locasale 11, Birgit Schilling 4,18 , Anu Suomalainen 3,12,13,18 & 1234567890():,; ✉ Eric Verdin 1,4,18 Mitochondrial acyl-coenzyme A species are emerging as important sources of protein modification and damage. Succinyl-CoA ligase (SCL) deficiency causes a mitochondrial encephalomyopathy of unknown pathomechanism. Here, we show that succinyl-CoA accumulates in cells derived from patients with recessive mutations in the tricarboxylic acid cycle (TCA) gene succinyl-CoA ligase subunit-β (SUCLA2), causing global protein hyper- succinylation. Using mass spectrometry, we quantify nearly 1,000 protein succinylation sites on 366 proteins from patient-derived fibroblasts and myotubes. Interestingly, hyper- succinylated proteins are distributed across cellular compartments, and many are known targets of the (NAD+)-dependent desuccinylase SIRT5. To test the contribution of hyper- succinylation to disease progression, we develop a zebrafish model of the SCL deficiency and find that SIRT5 gain-of-function reduces global protein succinylation and improves survival. Thus, increased succinyl-CoA levels contribute to the pathology of SCL deficiency through post-translational modifications.
    [Show full text]
  • Centenary Award and Sir Frederick Gowland Hopkins Memorial Lecture
    Centenary Award and Sir Frederick Gowland Hopkins Memorial Lecture Centenary Award and Sir Frederick Gowland Hopkins Memorial Lecture Seeing the invisible by paramagnetic and diamagnetic NMR G. Marius Clore*1 *Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0520, U.S.A. scale interdomain motions involved in ligand binding, and to the interaction of monomeric amyloid β-peptide with the surface of amyloid protofibrils and the internal cavity surface of Centenary Award and Sir Frederick the chaperonin GroEL. Gowland Hopkins Memorial Lecture Delivered at the MRC Laboratory of Molecular Biology, Cambridge, on Introduction 13 December 2012 Proteins and their complexes are not static but dynamic and Marius Clore are best described as an ensemble of states. The major species is located at the minimum of the free energy landscape and represents the species that has been studied with so much Abstract success by conventional structural and biophysical tech- niques, including crystallography and NMR. But the static Sparsely populated transient states of proteins and their picture revealed by these studies does not describe the complexes play an important role in many biological processes complete picture. In addition to the major species, there exist including protein–protein and protein–DNA recognition, al- highly transient sparsely populated states that arise from rare lostery, conformational selection, induced fit and self-assembly. excursions between the minimum free energy configuration These states are difficult to study as their low population and other local minima of the free energy landscape [1]. Given and transient nature makes them effectively invisible to that the populations of such sparsely populated states are so conventional structural and biophysical techniques.
    [Show full text]
  • Identification and Characterization of Posttranslational Modification-Specific Binding Proteins in Vivo by Mammalian Tethered Catalysis
    Identification and characterization of posttranslational modification-specific binding proteins in vivo by mammalian tethered catalysis Tanya M. Spektor and Judd C. Rice1 Department of Biochemistry and Molecular Biology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033 Communicated by C. David Allis, The Rockefeller University, New York, NY, July 14, 2009 (received for review February 26, 2009) Increasing evidence indicates that an important consequence of To overcome some of the limitations of in vitro approaches, a protein posttranslational modification (PTM) is the creation of a high previously undescribed in vivo method called yeast tethered catal- affinity binding site for the selective interaction with a PTM-specific ysis was developed (1). Briefly, an expressed fusion protein con- binding protein (BP). This PTM-mediated interaction is typically re- taining a target peptide sequence was tethered to an enzyme quired for downstream signaling propagation and corresponding resulting in the constitutive PTM of the peptide and, thereby, biological responses. Because the vast majority of mammalian pro- served as the bait in yeast two-hybrid screens for putative PTMBPs. teins contain PTMs, there is an immediate need to discover and Although this technique was used successfully to identify yeast characterize previously undescribed PTMBPs. To this end, we devel- PTMBPs, the ability to detect PTMBPs in higher eukaryotes is oped and validated an innovative in vivo approach called mammalian constrained by the limitations
    [Show full text]